Effect of Roxadustat in management of anemia and iron regulation in cirrhosis of liver patients

Effect of Roxadustat in management of anemia and iron regulation in cirrhosis of liver patients: a randomised control trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230615001

Enrollment

Registered

2023-06-15

Start date

2023-07-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis of liver patients who is anemic Anemia, Cirrhosis of Liver, Treatment with Roxadustat a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor

Interventions

60 patients with cirrosis of liver with anemia will be randomised to this group ,those will receive Roxadustat 50 mg ,thrice weekly for 6 weeks. Roxadustat is an orally administered , hypoxia inducibl

Experimental Drug,Sham Comparator Other

roxadustat 50 mg,Standard Medical Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with cirrhosis of liver (Child pugh A or B) 2. Anemia. 3. Age: More than 18 years

Exclusion criteria

Exclusion criteria: 1. Patients with Child Pugh C liver cirrhosis 2. Hepatocellular carcinoma 3. Pregnancy or lactation 4. Active variceal bleeding 5. Adult polycystic kidney disease 6. Hypo/Hyperthyroidism 7. Systemic Hypertension 8. Hyperkalemia 9. Patient with co-morbid condition (COPD, CKD, CCF, MI etc.)

Design outcomes

Primary

Measure	Time frame
Hemoglobin level 6 weeks hematology analyzer	—

Secondary

Measure	Time frame
serum hepcidin level 6 weeks ELISA,Serum Erythropoetin (EPO) level 6 weeks ELISA	—

Countries

Bangladesh

Contacts

Public ContactMd. Fakhrul Chowdhury

Bangabandhu Sheik Mujib Medical University

sawroshsmc@gmail.com01717109997

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026